Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ALRN
- Price
- 2.11
- Stock movement up
- +0.18 (9.33%)
- Company name
- Aileron Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 45.72M
- Ent value
- 82.05M
- Price/Sales
- 341.16
- Price/Book
- 0.91
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -66.86%
- 1 year return
- -45.90%
- 3 year return
- -78.88%
- 5 year return
- -61.82%
- 10 year return
- -
Last updated: 2025-04-04
DIVIDENDS
ALRN does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 341.16 |
| Price to Book | 0.91 |
| EV to Sales | 612.34 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 21.67M |
| EPS (TTM) | -1.35 |
| FCF per share (TTM) | -1.52 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 134.00K |
| Gross profit (TTM) | -63.00K |
| Operating income (TTM) | -29.62M |
| Net income (TTM) | -29.24M |
| EPS (TTM) | -1.35 |
| EPS (1y forward) | -1.88 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -47.01% |
| Operating margin (TTM) | -22102.24% |
| Profit margin (TTM) | -21821.64% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 17.65M |
| Net receivables | 0.00 |
| Total current assets | 18.68M |
| Goodwill | 6.33M |
| Intangible assets | 79.20M |
| Property, plant and equipment | 0.00 |
| Total assets | 104.22M |
| Accounts payable | 1.08M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 5.66M |
| Total liabilities | 53.99M |
| Shareholder's equity | 50.23M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -27.87M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -32.99M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -58.22% |
| Return on Assets | -28.06% |
| Return on Invested Capital | -58.22% |
| Cash Return on Invested Capital | -65.68% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.96 |
| Daily high | 2.17 |
| Daily low | 1.96 |
| Daily Volume | 63K |
| All-time high | 5964.00 |
| 1y analyst estimate | 13.00 |
| Beta | 2.34 |
| EPS (TTM) | -1.35 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 13 May 2025 |
Downside potential
Loading...
Downside potential data
| ALRN | S&P500 | |
| Current price drop from All-time high | -99.96% | -4.49% |
| Highest price drop | -99.98% | -56.47% |
| Date of highest drop | 2 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -86.68% | -11.07% |
| Avg time to new high | 237 days | 12 days |
| Max time to new high | 1828 days | 1805 days |
COMPANY DETAILS
Marketcap
45.72M
Marketcap category
Small-cap
Description
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.
Employees
15
Website
Investor relations
-
SEC filings
CEO
Manuel C. Aivado
Country
USA
City
Watertown
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner